About
Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, works by enhancing the body's natural ability to lower elevated blood glucose levels. It achieves this by preserving incretin hormones, which in turn stimulate insulin release from pancreatic beta cells and decrease glucagon secretion from alpha cells in a glucose-dependent manner. Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, complements this action by reducing glucose reabsorption in the kidneys, leading to increased urinary glucose excretion. This combination therapy provides a synergistic approach to managing type 2 diabetes, addressing different pathophysiological pathways to improve glycemic control. It also offers additional benefits related to cardiovascular and renal health, making it a comprehensive treatment option for eligible patients.
Uses
- Management of type 2 diabetes mellitus.
- Improvement of glycemic control.
- Reduction of risk of cardiovascular events in patients with established cardiovascular disease.
- Reduction of risk of progression of chronic kidney disease.
Directions For Use
Take one tablet orally once daily in the morning, with or without food, as advised by your healthcare provider.
Benefits
- Effective blood sugar reduction.
- Potential for modest weight loss.
- Cardioprotective effects.
- Renoprotective benefits.
- Low risk of hypoglycemia.
- Convenient once-daily administration.
Side Effects
- Genital mycotic infections
- Urinary tract infections
- Increased thirst
- Frequent urination
- Dizziness
- Hypotension
- Back pain
- Nasopharyngitis
- Ketoacidosis (rare)
- Fournier's gangrene (very rare)
- Pancreatitis (rare)
- Joint pain
Safety Measures
- Alcohol - Limit alcohol intake as it may increase the risk of dehydration and, rarely, ketoacidosis.
- Pregnancy - Avoid use during the second and third trimesters due to potential harm to fetal kidney development. Consult your doctor.
- Breastfeeding - Not recommended due to potential for drug excretion into breast milk and adverse effects on the infant.
- Liver - Use with caution in patients with severe hepatic impairment. No dose adjustment is typically required for mild to moderate impairment.
- Kidney - Contraindicated in severe renal impairment (eGFR <30 mL/min/1.73m²). Dose adjustments may be necessary for moderate impairment.
- Lung - Generally considered safe for patients with pre-existing lung conditions. No specific pulmonary precautions.
Disclaimer
MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.
Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.
Our goal is to complement, not replace, the essential doctor-patient relationship.
| Shipping Cost |
|
| Shop Location | Assam, India |
No comments found for this product. Be the first to comment!